Get notified when LUCD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Both auditors included a going-concern explanatory paragraph, signaling substantial doubt about the company's ability to continue operating.
- Dilution (new) — New investors face immediate dilution of $0.86 per share, with the offering price far above net tangible book value.
- Need For Additional Capital (new) — The company states it has not generated significant revenue or cash flow and will need more capital even after this offering, which could further dilute existing holders.
Lucid Diagnostics prices $18M offering of 18M shares at $1.00 each; net proceeds $16.8M
Filed April 23, 2026 · ~2 min read
Key Changes
-
high
Lucid Diagnostics is selling 18,000,000 new shares at $1.00 per share, raising $18.0 million gross before underwriting discounts and expenses.
The Offering verify on EDGAR → -
high
Net proceeds to the company are approximately $16.8 million after deducting $1.2 million in underwriting discounts, commissions, and offering expenses.
Use of Proceeds verify on EDGAR → -
medium
The company intends to use the net proceeds for working capital and general corporate purposes, with no specific amounts identified for any particular purpose.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GIS 10-Q) is open in full — no account needed.
Partner
Trade LUCD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify